Business Wire

HIRO-CAPITAL

7.2.2020 01:03:10 CET | Business Wire | Press release

Share
Next Generation Sports Wearable Pioneer NURVV Secures $9 Million Venture Round Led by Hiro Capital for its Revolutionary NURVV Run Insoles and Coaching App

Fresh from a legendary launch at CES 2020, NURVV – the biomechanics innovator using British science to disrupt the global wearables industry – is today announcing it has closed its first venture funding round, led by Hiro Capital.

Hiro Capital – the new Sports technology, Games and Esports VC Fund led by Inspired Entertainment co-founder Luke Alvarez, Games Workshop co-founder Ian Livingstone CBE and Cherry Freeman, co-founder of LoveCrafts - has invested $9m in NURVV’s husband and wife team of serial entrepreneurs Jason and Ulrica Roberts.

The money will be used to bring NURVV’s debut product, NURVV Run, to a global market; to fund further research and development into its patented biomechanics sensor technologies and to support the founders in achieving their aim of helping 10 million runners to improve their technique.

NURVV Run was unveiled at this year’s Pepcom during the Consumer Electronics Show in Las Vegas to great acclaim, featuring on multiple Best of CES lists from the likes of Wired, CNET and Gear Patrol. NURVV Run also won US Today’s Editor’s Choice award which handpicks winners that strike a balance in innovation, technology, design, and value.

Tested by hundreds of athletes, universities and leading institutions including SATRA Technology and the National Physical Laboratory over the past three years, the system uses 32 high-precision sensors fitted inside lightweight insoles to accurately capture data from the feet at 1,000 times per second, per sensor.

This data, which includes unique running metrics such as cadence, step length, footstrike, pronation and balance, is fed into the NURVV Run coaching app to show a complete picture of the wearer’s running technique. It uses advanced biomechanics to deliver simple, actionable insights as well as personalised coaching that gives guidance on how to improve before, during and after each run.

Its in-run, real-time coaching creates gamified speed and technique workouts to help wearers run at a target pace, to a chosen finish time or beat a personal record with responsive audio, visual and haptic feedback. Real-time prompts detailing step length, cadence and pace on critical splits also help keep runners on track to hit their goals.

This not only helps runners improve their technique and pace, it can help reduce injury via a Running Health score.

The Running Health score helps reduce injury by analysing each runner’s training load, pronation, cadence and balance – to identify problem areas before they become serious. Runners can also optimise their training with recommendations on the right distance to run to achieve their optimal training zone and avoid overtraining.

The NURVV Run insoles are compatible with all running shoes, are rain and mud proof and come with a five-hour active battery life. The system ships with two GPS trackers and access to the free NURVV Run Coaching app. Runners can connect the system to IOS, Apple Watch, Android and to ANT+ (Garmin) wearables.

“Runners are already able to collect a huge amount of data about each and every run they do. However, most of what they capture is historic, inaccurate and provides few insights on how to be a better runner,” said Jason Roberts, founder and CEO of NURVV. “NURVV Run revolutionises how people run by accurately capturing the metrics that matter most, directly from the point of action at the foot, before using live coaching to help them improve in a simple, easy-to-understand way.”

“From the very beginning of this journey we kept coming back to the same question: ‘Why is running measured from the wrist, when most of the important metrics happen at the feet?’,” added co-founder Ulrica Roberts. “Driven by the idea we could revolutionise running by putting core biomechanical principles at the heart of our solution, we sought out the expertise to make it happen.”

“Combining our cutting-edge wearable technology, in-house biomechanics expertise, and ongoing dialogue with the running community, NURVV Run is the most comprehensive tool for runners who crave more detailed information on their performance and technique,” said Dr. Grant Trewartha, head of biomechanics at NURVV.

Luke Alvarez, Managing Partner of Hiro, said: “Hiro is delighted to be investing in NURVV as our Fund’s fourth deal and our first Sports tech investment. NURVV’s success comes from putting the athlete’s body at the heart of everything they do. NURVV is based on fundamental patented sensor technologies combined with deep biomechanics and data science that have revolutionary potential across sports, gaming, VR/AR and wellness. Jason and Ulrica are extraordinary entrepreneurs and we are excited to be working with them and their team to take NURVV to the next level.”

NURVV Run has been tested during 22 million steps of durability testing and 30,000 miles covered on the road.

ENDS

About NURVV

NURVV is on a mission to provide runners with the power to understand what their bodies are truly capable of and find their true potential. We pioneer the latest advances in technology and biomechanics. We capture running from the point of action and analyze run-data using advanced biomechanics to deliver actionable insights and live in-run coaching. We are dedicated to all runners who want to improve their running and aim to change 10 million lives with a new way of knowing by 2025. https://www.nurvv.com/

About Hiro Capital

Hiro Capital is a Luxembourg / London technology Venture Capital fund which invests in European and UK innovators in Games, Esports and Digital Sports. Hiro Capital generally invests at the post-seed Series A and B stages. We invest both in front-end Content creators in Games, Esports and Digital Sports and in deep tech sector-specific applications of Cloud, Mobile, Streaming, Big Data, AI, Wearables, AR and VR technologies.

We back experienced entrepreneurial teams, building innovative technologies and content with a strongly differentiated proposition and with the scaling opportunity to become very large.

We are Games, Esports and Sports investors who are also Games, Esports and Sports entrepreneurs. Our core belief is that Games, Esports and Digital Sports will be a central pillar of Entertainment, Economic and Social Life in the mid 21st century. We invest in the innovators who are building that future. https://hiro.capital/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye